# Phase I Vandetanib Plus Capecitabine, Oxaliplatin and Bevacizumab for Metastatic Colorectal Cancer

> **NCT00532909** · PHASE1 · COMPLETED · sponsor: **Branimir Sikic** · enrollment: 13 (actual)

## Conditions studied

- Anal, Colon, and Rectal Cancers
- Colorectal Neoplasms
- Colon/Rectal Cancer

## Interventions

- **DRUG:** Vandetanib
- **DRUG:** Capecitabine
- **DRUG:** Oxaliplatin
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT00532909
- **Lead sponsor:** Branimir Sikic
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** 2010-05
- **Final completion:** 2010-05
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2012-07-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00532909

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00532909, "Phase I Vandetanib Plus Capecitabine, Oxaliplatin and Bevacizumab for Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00532909. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*